Sidney Kimmel Comprehensive Cancer Center At Thomas Jefferson University

This study tested the drug nivolumab in 26 people with stage IIB or IIC melanoma that had been completely removed by surgery. The goal was to see if nivolumab, an immunotherapy that helps the immune system attack cancer cells, could prevent the melanoma from coming back. Particip…

This phase 2 trial tested whether certain biomarkers in bone marrow can predict how well patients with high-risk acute myeloid leukemia (AML) respond to treatment with sirolimus plus standard chemotherapy (MEC). The study enrolled 39 adults with AML that was hard to treat or had …

This study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…

This phase 2 trial tested a two-step stem cell transplant approach for 47 patients with high-risk blood cancers like leukemia and lymphoma. The method uses the drug cyclophosphamide to lower the chance of graft-versus-host disease (GVHD), a common complication. The goal was to se…

This early study tested a combination of heat therapy (hyperthermia) and high-dose radiation for men whose prostate cancer returned after earlier radiation. Only 3 men took part, and the main goal was to check safety and side effects. The approach aims to make cancer cells more s…

This phase 2 trial tested a two-step donor stem cell transplant in 51 people with high-risk blood cancers. The approach uses total-body irradiation and chemotherapy to prepare the body, then infuses donor stem cells and later donor immune cells. The goal is to boost the anti-canc…

This study looked at whether patients with multiple myeloma or non-Hodgkin lymphoma could safely skip a drug called tbo-filgrastim after a stem cell transplant and still recover quickly. The drug is normally given to boost white blood cells. The trial compared two groups: one tha…

This study tested whether giving the drug cyclophosphamide after a stem cell transplant could help prevent a serious complication called graft-versus-host disease (GVHD) in 78 blood cancer patients. The approach aimed to make transplants from less-than-perfect donors as safe and …

This phase II trial tested two drugs—sirolimus and azacitidine—in 57 people with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that had come back or didn't respond to standard treatment. The goal was to see if the combination could shrink or control the…

This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…

This pilot study tested whether placing tiny radioactive seeds (Cesium-131) into the wound during surgery can kill leftover cancer cells in patients whose head and neck cancer has come back. Thirty adults with resectable tumors received the implant right after tumor removal. Rese…

This pilot study tested whether vitamin B6 supplements can reduce hot flashes in 43 men with prostate cancer who were receiving hormone therapy (ADT). Hot flashes are a common side effect of this treatment. The study measured how bothersome hot flashes were before and after 8 and…

This study tested whether a neighborhood-based educational program could increase knowledge about prostate cancer and screening among 239 men living in high-risk areas. Participants learned about the pros and cons of screening, and researchers measured changes in decision-making …

This pilot study tested a new maskless immobilization device (MID) for patients with head and neck cancers or brain tumors undergoing radiation therapy. The goal was to see if the device could keep patients as still and accurate as the standard thermoplastic mask. Only 12 patient…